A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer

B. Liu,L. Liu, J. Ran,N. Xie, J. Li,H. Xiao, X. Yang,C. Tian,H. Wu, J. Lu, J. Gao, X. Hu, M. Cao, Z. Shui,Z.-Y. Hu, Q. Ouyang

ESMO Open（2023）

引用 0|浏览0

暂无评分

摘要

•Eribulin combined with anlotinib can significantly improve the PFS of eribulin monotherapy.•Combination therapy group has manageable toxicity with similar adverse event spectrum compared with the monotherapy group.•Circulating tumor DNA aberrations in PIK3CA, ESR1, GATA3 (PEG) were marginally related to the higher objective response rate in the eribulin plus anlotinib group.•Eribulin plus anlotinib can be considered an alternative treatment option for HER2-negative advanced breast cancer.

查看译文

关键词

eribulin monotherapy,metastatic breast cancer,breast cancer,anlotinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要